IDEXX LABORATORIES INC (IX1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IX1 - US45168D1046 - Common Stock
568.8 EUR
-12.8 (-2.2%)
We assign a fundamental rating of 6 out of 10 to IX1. IX1 was compared to 62 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IX1 a very profitable company, without any liquidiy or solvency issues. IX1 is quite expensive at the moment. It does show a decent growth rate. With these ratings, IX1 could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
In the past year IX1 was profitable.
IX1 had a positive operating cash flow in the past year.
IX1 had positive earnings in each of the past 5 years.
In the past 5 years IX1 always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 30.34%, IX1 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Looking at the Return On Equity, with a value of 65.81%, IX1 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Return On Invested Capital of IX1 (40.25%) is better than 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IX1 is significantly above the industry average of 9.74%.
The 3 year average ROIC (35.08%) for IX1 is below the current ROIC(40.25%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.25% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
1.3 Margins
IX1's Profit Margin of 24.65% is amongst the best of the industry. IX1 outperforms 95.16% of its industry peers.
In the last couple of years the Profit Margin of IX1 has grown nicely.
IX1 has a better Operating Margin (31.34%) than 100.00% of its industry peers.
In the last couple of years the Operating Margin of IX1 has grown nicely.
With a Gross Margin value of 61.72%, IX1 perfoms like the industry average, outperforming 59.68% of the companies in the same industry.
In the last couple of years the Gross Margin of IX1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IX1 is creating value.
Compared to 1 year ago, IX1 has less shares outstanding
IX1 has less shares outstanding than it did 5 years ago.
The debt/assets ratio for IX1 has been reduced compared to a year ago.
2.2 Solvency
IX1 has an Altman-Z score of 22.67. This indicates that IX1 is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of IX1 (22.67) is better than 100.00% of its industry peers.
The Debt to FCF ratio of IX1 is 1.04, which is an excellent value as it means it would take IX1, only 1.04 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.04, IX1 belongs to the top of the industry, outperforming 88.71% of the companies in the same industry.
IX1 has a Debt/Equity ratio of 0.53. This is a neutral value indicating IX1 is somewhat dependend on debt financing.
IX1 has a worse Debt to Equity ratio (0.53) than 61.29% of its industry peers.
Even though the debt/equity ratio score it not favorable for IX1, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 22.67 |
ROIC/WACC4.39
WACC9.17%
2.3 Liquidity
IX1 has a Current Ratio of 1.18. This is a normal value and indicates that IX1 is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of IX1 (1.18) is worse than 69.35% of its industry peers.
IX1 has a Quick Ratio of 1.18. This is a bad value and indicates that IX1 is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.87, IX1 is doing worse than 64.52% of the companies in the same industry.
IX1 does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 15.16% over the past year.
The Earnings Per Share has been growing by 18.18% on average over the past years. This is quite good.
IX1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.39%.
IX1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.12% yearly.
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
3.2 Future
IX1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.81% yearly.
The Revenue is expected to grow by 9.18% on average over the next years. This is quite good.
EPS Next Y16.89%
EPS Next 2Y14.65%
EPS Next 3Y14.13%
EPS Next 5Y13.81%
Revenue Next Year10.46%
Revenue Next 2Y9.59%
Revenue Next 3Y9.39%
Revenue Next 5Y9.18%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 53.01, which means the current valuation is very expensive for IX1.
IX1's Price/Earnings is on the same level as the industry average.
IX1's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.77.
IX1 is valuated quite expensively with a Price/Forward Earnings ratio of 45.22.
Based on the Price/Forward Earnings ratio, IX1 is valued a bit more expensive than 67.74% of the companies in the same industry.
IX1's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 53.01 | ||
| Fwd PE | 45.22 |
4.2 Price Multiples
IX1's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. IX1 is more expensive than 64.52% of the companies in the same industry.
IX1's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 56.79 | ||
| EV/EBITDA | 37.14 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
IX1 has an outstanding profitability rating, which may justify a higher PE ratio.
IX1's earnings are expected to grow with 14.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.14
PEG (5Y)2.92
EPS Next 2Y14.65%
EPS Next 3Y14.13%
5. Dividend
5.1 Amount
IX1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IX1 (12/30/2025, 7:00:00 PM)
568.8
-12.8 (-2.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners94.91%
Inst Owner ChangeN/A
Ins Owners0.21%
Ins Owner ChangeN/A
Market Cap45.42B
Revenue(TTM)4.17B
Net Income(TTM)1.03B
Analysts80.95
Price Target687.11 (20.8%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)36.99%
PT rev (3m)36.99%
EPS NQ rev (1m)0.09%
EPS NQ rev (3m)8.6%
EPS NY rev (1m)2.21%
EPS NY rev (3m)7.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.15%
Revenue NY rev (1m)1.25%
Revenue NY rev (3m)3.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 53.01 | ||
| Fwd PE | 45.22 | ||
| P/S | 12.81 | ||
| P/FCF | 56.79 | ||
| P/OCF | 49.08 | ||
| P/B | 34.2 | ||
| P/tB | 51.71 | ||
| EV/EBITDA | 37.14 |
EPS(TTM)10.73
EY1.89%
EPS(NY)12.58
Fwd EY2.21%
FCF(TTM)10.02
FCFY1.76%
OCF(TTM)11.59
OCFY2.04%
SpS44.39
BVpS16.63
TBVpS11
PEG (NY)3.14
PEG (5Y)2.92
Graham Number63.36
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.25% | ||
| ROICexc | 43.77% | ||
| ROICexgc | 56.25% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
ROICexc(3y)39.8%
ROICexc(5y)41.54%
ROICexgc(3y)51.52%
ROICexgc(5y)54.7%
ROCE(3y)52.73%
ROCE(5y)50.92%
ROICexgc growth 3Y-5.99%
ROICexgc growth 5Y4.28%
ROICexc growth 3Y-3.86%
ROICexc growth 5Y4.07%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 22.67 |
F-Score8
WACC9.17%
ROIC/WACC4.39
Cap/Depr(3y)119.67%
Cap/Depr(5y)117.13%
Cap/Sales(3y)3.91%
Cap/Sales(5y)3.89%
Profit Quality(3y)79.31%
Profit Quality(5y)83.23%
High Growth Momentum
Growth
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
EPS Next Y16.89%
EPS Next 2Y14.65%
EPS Next 3Y14.13%
EPS Next 5Y13.81%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
Revenue Next Year10.46%
Revenue Next 2Y9.59%
Revenue Next 3Y9.39%
Revenue Next 5Y9.18%
EBIT growth 1Y17.46%
EBIT growth 3Y6.64%
EBIT growth 5Y15.38%
EBIT Next Year33.04%
EBIT Next 3Y18.01%
EBIT Next 5Y14.77%
FCF growth 1Y38.31%
FCF growth 3Y7.86%
FCF growth 5Y21.3%
OCF growth 1Y31.08%
OCF growth 3Y7.13%
OCF growth 5Y15.14%
IDEXX LABORATORIES INC / IX1.DE FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IX1.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to IX1.DE.
Can you provide the valuation status for IDEXX LABORATORIES INC?
ChartMill assigns a valuation rating of 2 / 10 to IDEXX LABORATORIES INC (IX1.DE). This can be considered as Overvalued.
What is the profitability of IX1 stock?
IDEXX LABORATORIES INC (IX1.DE) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for IX1 stock?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IX1.DE) is 53.01 and the Price/Book (PB) ratio is 34.2.